Skip to content

Study · Case report or series · n = 1 · 2026

8 results

Tirzepatide-Induced Liver Injury: A Rare Complication.

Spaeth LD, Jordan KM, Barlow MP, Cottrell DA

AACE endocrinology and diabetes26 Nov 2025Cited by 2 (Europe PMC)

PMID41938310 (opens in a new tab)PMCIDPMC13043485 (opens in a new tab)DOI10.1016/j.aed.2025.11.009 (opens in a new tab)PepBankPUB-41938310
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In one 60-year-old woman with type 2 diabetes and obesity, alanine transaminase rose to 1562 U/L within 24 hours after tirzepatide 2.5 mg weekly.

    In plain wordsIn one woman with type 2 diabetes and obesity, alanine transaminase rose after tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAlanine transaminase
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    2.5 mg weekly · 21 daysAs given in this study (human).

    Measurements

    Alanine transaminase
    1562 U/L
    within 24 hours

    Source sentences

    Summary
    Alanine transaminase and aspartate transferase rose from mildly elevated to 1562 U/L and 1466 U/L (normal 0-35 U/L), respectively, in 24 hours, disproportionately versus alkaline phosphatase and bilirubin.
    1 context sentence
    Summary · context
    A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.
  2. 02HumanCase report or seriesSafety outcome

    In one 60-year-old woman with type 2 diabetes and obesity, aspartate transferase rose to 1466 U/L within 24 hours after tirzepatide 2.5 mg weekly.

    In plain wordsIn one woman with type 2 diabetes and obesity, aspartate transferase rose after tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAspartate transferase
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    2.5 mg weekly · 21 daysAs given in this study (human).

    Measurements

    Aspartate transferase
    1466 U/L
    within 24 hours

    Source sentences

    Summary
    Alanine transaminase and aspartate transferase rose from mildly elevated to 1562 U/L and 1466 U/L (normal 0-35 U/L), respectively, in 24 hours, disproportionately versus alkaline phosphatase and bilirubin.
    1 context sentence
    Summary · context
    A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.
  3. 03HumanCase report or seriesSafety outcome

    In one woman with type 2 diabetes and obesity, liver enzymes normalized 24 days after stopping tirzepatide.

    In plain wordsIn one woman with type 2 diabetes and obesity, liver enzymes normalized 24 days after stopping tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseLiver enzyme normalization after discontinuation
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    2.5 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Following drug discontinuation, liver enzymes normalized after 24 days.
    1 context sentence
    Summary · context
    A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.
  4. 04HumanCase report or seriesSafety outcome

    In one woman with type 2 diabetes and obesity, aminotransferases remained normal at three months after tirzepatide was withheld.

    In plain wordsIn one woman with type 2 diabetes and obesity, aminotransferases remained normal 3 months after tirzepatide was stopped.

    Peptide
    Tirzepatide
    Outcome
    Not applicableAminotransferases at 3 months
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    2.5 mg weeklyAs given in this study (human).

    Source sentences

    Summary
    Home medications were resumed except for tirzepatide, and aminotransferases remained normal at 3 months.
    1 context sentence
    Summary · context
    A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.
  5. 05HumanCase report or seriesSafety outcome

    In one woman with type 2 diabetes and obesity, prior semaglutide exposure was reported without hepatotoxicity.

    In plain wordsIn one woman with type 2 diabetes and obesity, prior semaglutide exposure was reported without hepatotoxicity.

    Peptide
    Semaglutide
    Outcome
    Not applicableHepatotoxicity during prior exposure
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    She previously received semaglutide and liraglutide (total 7 years) without hepatotoxicity.
    1 context sentence
    Summary · context
    A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.
  6. 06HumanCase report or seriesSafety outcome

    In one woman with type 2 diabetes and obesity, prior liraglutide exposure was reported without hepatotoxicity.

    In plain wordsIn one woman with type 2 diabetes and obesity, prior liraglutide exposure was reported without hepatotoxicity.

    Peptide
    Liraglutide
    Outcome
    Not applicableHepatotoxicity during prior exposure
    Study

    n = 1

    Outcome group
    Adverse events · Liver
    Studied dose
    Dose not stated

    Source sentences

    Summary
    She previously received semaglutide and liraglutide (total 7 years) without hepatotoxicity.
    1 context sentence
    Summary · context
    A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.
  7. 07HumanCase report or seriesSafety outcome

    A 60-year-old woman with type 2 diabetes and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.

    In plain wordsIn one woman with type 2 diabetes and obesity, epigastric pain was reported 21 days after starting tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableEpigastric pain
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    2.5 mg weekly · 21 daysAs given in this study (human).

    Source sentences

    Summary
    A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.
  8. 08HumanCase report or seriesSafety outcome

    In a 60-year-old woman with type 2 diabetes and obesity, isolated right upper quadrant abdominal tenderness was present after starting tirzepatide.

    In plain wordsIn one woman with type 2 diabetes and obesity, right upper quadrant abdominal tenderness was reported after starting tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    Not applicableRight upper quadrant abdominal tenderness
    Study

    n = 1

    Outcome group
    Adverse events · Gastrointestinal
    Studied dose
    2.5 mg weekly · 21 daysAs given in this study (human).

    Source sentences

    Summary
    Isolated right upper quadrant abdominal tenderness was present.
    1 context sentence
    Summary · context
    A 60-year-old woman with type 2 diabetes mellitus and obesity presented with epigastric pain 21 days after starting tirzepatide 2.5 mg weekly.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.